Leveraging the Tumor Microenvironment as a Target for Cancer Therapeutics: A Review of Emerging Opportunities
Hakan Guven1, Zoltán Székely2,3,4,5
1Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, 675 Hoes Lane West, Piscataway, NJ 08854, USA.
Abstract:
Cancer has remained one of the leading causes of death worldwide throughout history despite significant advancements in drug development, radiation therapy, and surgery. Traditional chemotherapeutic small molecules are often hindered by narrow therapeutic indices and limited specificity, leading to suboptimal clinical outcomes. On the other hand, more advanced approaches, such as antibody-drug conjugates (ADCs), frequently encounter obstacles, including poor tumor penetration and prohibitive production costs. The tumor-forming and metastatic capacity of cancer further challenges currently available cancer therapies by creating a biochemical milieu known as the tumor microenvironment (TME). Although solid tumor development presents significant obstacles, it also opens new avenues for innovative therapeutic approaches. It is well-documented that as tumors grow beyond 1-2 mm3 in size, they undergo profound changes in their microenvironment, including alterations in oxygen levels, pH, enzymatic activity, surface antigen expression, and the cellular composition of the stroma. These changes create unique opportunities that can be exploited to develop novel and innovative therapeutics. Currently, numerous ADCs, small-molecule-drug conjugates (SMDCs), and prodrugs are being developed to target specific aspects of these microenvironmental changes. In this review, we explore five TME parameters in detail, with a focus on their relevance to specific cancer types, phenotypic identifiers, and preferred methods of therapeutic targeting. Additionally, we examine the chemical moieties available to target these changes, providing a framework for design strategies that exploit the dynamics of the tumor microenvironment.
Insights
Cancer therapies face challenges from the tumor microenvironment (TME). This review explores targeting TME changes for novel therapeutics like antibody-drug conjugates (ADCs) and small-molecule-drug conjugates (SMDCs).
Area of Science:
- Oncology
- Biochemistry
- Drug Development
Background:
- Traditional cancer treatments like chemotherapy have limitations including narrow therapeutic indices and poor specificity.
- Advanced therapies such as antibody-drug conjugates (ADCs) face challenges like poor tumor penetration and high production costs.
- The tumor microenvironment (TME) presents unique biochemical conditions that both hinder and offer opportunities for cancer therapies.
Purpose of the Study:
- To review five key parameters of the tumor microenvironment (TME) that can be therapeutically targeted.
- To discuss the relevance of these TME parameters to specific cancer types and phenotypic identifiers.
- To examine available chemical moieties and design strategies for exploiting TME dynamics in cancer treatment.
Main Methods:
- Literature review focusing on the tumor microenvironment (TME) and its impact on cancer therapy.
- Analysis of five specific TME parameters: oxygen levels, pH, enzymatic activity, surface antigen expression, and stromal composition.
- Examination of therapeutic strategies including antibody-drug conjugates (ADCs), small-molecule-drug conjugates (SMDCs), and prodrugs.
Main Results:
- Solid tumors undergo significant microenvironmental changes as they grow, creating unique therapeutic targets.
- Specific TME parameters can be targeted using various drug delivery systems like ADCs and SMDCs.
- The review provides a framework for designing therapeutics that exploit TME characteristics.
Conclusions:
- The tumor microenvironment (TME) offers exploitable characteristics for developing novel and more effective cancer therapies.
- Targeting specific TME parameters can overcome limitations of traditional and advanced cancer treatments.
- Understanding TME dynamics is crucial for designing next-generation cancer therapeutics.
More Related Videos
05:48Tissue Engineering of Tumor Stromal Microenvironment with Application to Cancer Cell Invasion
Published on: March 18, 2014
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle
01:15Drugs that Stabilize Microtubules